Trial Profile
A Study to Evaluate the Clinical Pharmacokinetics of Vemurafenib in Patients With BRAF-Mutated Melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2016
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- 12 Jul 2016 New trial record
- 01 Jul 2016 Results published in the Journal of Clinical Pharmacology